

## **Our commitment to transparency in financial relationships with healthcare professionals and healthcare organisations**

Novo Nordisk is committed to driving change in diabetes, obesity and other chronic diseases. This includes providing as much information as we can to healthcare professionals, healthcare organisations and patients about the proper use of the medicines and delivery systems we manufacture.

Collaborations with healthcare professionals and healthcare organisations help us drive innovation and develop new medicines, enhance quality of health education and identify patient needs.

Novo Nordisk supports transparency and is committed to compliance with disclosing our financial relationships related to our collaborations with the medical community as required by our industry guidelines, namely the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice. We believe the transparency of financial relationships between those with whom we collaborate is very important to maintaining trust-based relationships with our patients and the public.

Please refer to the Patient Associations Disclosure 2023 link for the transactions Novo Nordisk has made to patient organisations in 2023. As a member of the IPHA, Novo Nordisk is required to make public details of payments and transfers of value (ToV) or in kind made to Irish healthcare professionals and healthcare organisations in 2023. This ToV will be published in June 2024 on [www.transferofvalue.ie](http://www.transferofvalue.ie).

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S  
IE24NNG00052, May 2024

